checkAd
    EyePoint Pharmaceuticals Aktie
    1,2150
     
    USD
    +13,02 %
    +0,1400 USD
    Letzter Kurs 30.03.18 NYSE
    ISIN: US74440J1016 · WKN: A0Q4DQ · USA

    Neueste Nachrichten

    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.04.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
    02.04.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    18.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
    07.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
    04.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
    29.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
    27.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
    03.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.01.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
    10.01.24 · globenewswire · EyePoint Pharmaceuticals